Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC trimmed its holdings in Pyxis Oncology, Inc. (NASDAQ:PYXS) by 34.5% in the second quarter, Holdings Channel.com reports. The institutional investor owned 96,936 shares of the company’s stock after selling 51,064 shares during the quarter. Renaissance Technologies LLC’s holdings in Pyxis Oncology were worth $321,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Fullcircle Wealth LLC acquired a new stake in shares of Pyxis Oncology in the second quarter valued at about $40,000. SG Americas Securities LLC purchased a new position in Pyxis Oncology during the first quarter worth about $59,000. Cetera Advisors LLC purchased a new position in Pyxis Oncology during the first quarter worth about $100,000. Schulhoff & Co. Inc. boosted its stake in Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after buying an additional 20,000 shares during the period. Finally, American Century Companies Inc. boosted its stake in shares of Pyxis Oncology by 56.0% in the second quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after purchasing an additional 20,901 shares during the period. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Stock Up 2.4 %

Shares of NASDAQ:PYXS opened at $3.23 on Friday. The firm’s 50 day moving average price is $3.53 and its 200 day moving average price is $3.82. The stock has a market cap of $190.21 million, a price-to-earnings ratio of -2.38 and a beta of 1.27. Pyxis Oncology, Inc. has a fifty-two week low of $1.35 and a fifty-two week high of $6.85.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. On average, equities analysts anticipate that Pyxis Oncology, Inc. will post -1.07 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently commented on PYXS. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Thursday, September 19th. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research note on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $9.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.